Indivior PLC (NASDAQ:INDV) to Post Q2 2024 Earnings of $0.38 Per Share, Northland Capmk Forecasts

Indivior PLC (NASDAQ:INDV) – Equities researchers at Northland Capmk lowered their Q2 2024 earnings estimates for shares of Indivior in a research note issued to investors on Monday, July 1st. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.38 for the quarter, down from their previous forecast of $0.46. The consensus estimate for Indivior’s current full-year earnings is $2.00 per share. Northland Capmk also issued estimates for Indivior’s Q3 2024 earnings at $0.43 EPS and Q4 2024 earnings at $0.55 EPS.

Separately, Craig Hallum started coverage on shares of Indivior in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price objective for the company.

Indivior Price Performance

NASDAQ:INDV opened at $15.75 on Tuesday. The stock has a fifty day moving average of $17.25 and a 200 day moving average of $18.09. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 1,575.00 and a beta of 0.69. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92. Indivior has a 52-week low of $14.38 and a 52-week high of $24.90.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million for the quarter, compared to analysts’ expectations of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%.

Hedge Funds Weigh In On Indivior

Large investors have recently modified their holdings of the stock. Scopia Capital Management LP purchased a new stake in Indivior in the third quarter worth approximately $191,743,000. Vanguard Group Inc. boosted its position in shares of Indivior by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock valued at $134,875,000 after acquiring an additional 90,673 shares during the last quarter. Norges Bank bought a new stake in Indivior during the fourth quarter worth approximately $36,011,000. UBS Group AG raised its stake in shares of Indivior by 71.9% in the fourth quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after acquiring an additional 345,556 shares during the period. Finally, Renaissance Group LLC boosted its holdings in Indivior by 6.1% during the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock valued at $1,573,000 after acquiring an additional 5,896 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.